Vitrolife: No surprises in Q4 after pre-announcement - ABG

Sales and EBITDA inline with pre-announcement
31% organic growth in Technology
Estimates likely up 1-2% on EBITDA


Q4 results

Vitrolife pre-announced Q4 sales and EBITDA and the impairment charge of SEK 4.3bn on January 23, 2023, and the reported figures for sales and EBITDA came in pre-announced, ie Q4 sales came in at SEK 904m and EBITDA came in at SEK 294m. Compared to estimates ahead of the pre-announcement, sales came in 1.7% above consensus (+2.5% vs ABGSCe) and EBITDA came in 1.7% above consensus (+1.6% vs ABGSCe). Pretax profit in Q4 (not pre-announced) came in at SEK -4,130m and adjusted for the impairment at SEK 170m (+10%% vs ABGSCe at SEK 155m, no cons). In terms of sales by product types (not pre-announced) Technology had a strong quarter with sales of SEK 206m (+29% vs ABGSCe, no cons), Consumables with sales of SEK 358m (-4% vs ABGSCe, no cons) and Genetic Services had sales of SEK 340m (-2% vs ABGSCe, no cons)

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/Vitrolife/Equity-research/2024/2/vitrolife---no-surprises-in-q4-after-pre-announcement/